SECONDARY HYPERPARATHYROIDISM AMONG END-STAGE RENAL DISEASE PATIENTS
DOI:
https://doi.org/10.22159/ijms.2020.v8i6.39598Keywords:
Chronic kidney disease, Secondary hyperparathyroidism, Parathyroid hormone, Calcium, Phosphate, Creatinine, vitamin DAbstract
Objectives: The study aims to determine the incidence of secondary hyperparathyroidism (SHPT) in chronic kidney disease patients, the correlation between creatinine, parathyroid hormone (PTH) and phosphate, and calcium in renal disease.
Methods: A retrospective cross-sectional study was performed, a total of 100 hemodialysis patients’ reports were analyzed from January 2019 to December 2019, at Hebron Governmental Hospital, in Hebron, Palestine. The patients’ data were collected, including creatinine level, calcium, and phosphorus in addition to PTH concentrations. Twenty-five healthy persons with normal kidney function were also included in the study as a control for comparison. Statistical Package for the Social Sciences version 22 was used to analyze the data. T-test and Pearson’s tests were used to study the results. R (Pearson’s test) was used to determine the correlation between creatinine, PTH, phosphate, and calcium.
Results: The mean values of serum of creatinine, phosphate, calcium, and PTH were determined for both patients and the control. Levels of PTH were significantly higher in kidney failure patients and positively correlated with creatinine and phosphate. However, levels of PTH were significantly negatively correlated with calcium. All patients included in the study have very high levels of PTH PTH. This increase might be due to many factors that contributed to the hypersecretion of PTH. The correlations between these predisposing factors of SHPT are explained.
Conclusion: The study showed that SHPT is common among patients with end-stage renal disease. The most complications of SHPT are mineral and bone metabolism disorders and cardiovascular diseases. Thus, early detection and treatment of SHPT may control these complications.
References
Movahed SM, Mousavi SS, Faramarzi M. Secondary hyperparathyroidism among end-stage renal disease patients in Beharlou hospital, Tehran Province, Iran. J Parathyr Dis 2018;6:64-7.
Yuen NK, Ananthakrishnan S, Campbell MJ. Hyperparathyroidism of renal disease. Perm J 2016;20:15-127.
Slatopolsky E, Brown A, Dusso A. Pathogenesis of secondary hyperparathyroidism. Kidney Int 1999;56:S14-9.
Sliem H, Tawfik G, Moustafa F, Zaki H. Relationship of associated secondary hyperparathyroidism to serum fibroblast growth factor-23 in end-stage renal disease: A case-control study. Indian J Endocrinol Metab 2011;15:105-9.
Veldurthy V, Wei R, Oz L, Dhawan P, Jeon YH, Christakos S. Vitamin D, calcium homeostasis, and aging. Bone Res 2016;4:16041.
Arora K, Goyal G, Soin D, Kumar S, Arora H, Garg C. Correlation of parathyroid hormone levels with mineral status in end-stage renal disease patients. Indian J Endocrinol Metab 2018;22:735-9.
Published
How to Cite
Issue
Section
Copyright (c) 2020 Asmaa J Alkomi, Razan F Jubeh, Safaa A Erjoub, Hanaa Kh Aldraweesh, Haya A Alawawdah, Rozan Attili, Hatem A Hejaz
This work is licensed under a Creative Commons Attribution 4.0 International License.
